Regional Dynamics
Regional segmentation of theglobal HepatocellularCarcinoma Drugs Market by Coherent Market Insights comprises North America,Latin America, Europe, Asia Pacific, Middle East, and Africa. North America isexpected to hold a dominant position in the global hepatocellular carcinomadrugs market over the forecast period, owing to increasing prevalence of thedisease and the rising number of clinical trials undertaken by themanufacturers to address the unmet medical needs of the patients. According tothe survey by the Health Science Department, University of California, LosAngeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for threequarters of liver cancers in the U.S. with an estimated 40,000 Americansdiagnosed with liver cancer in 2017 and more than 28,000 deaths are reportedfrom the disease. Also, in April 2018, Eli Lilly and Company completed Phase 3research study of Cyramza (ramucirumab) as a single agent in the second-linetreatment of people with hepatocellular carcinoma, also known as liver cancer.
Asia Pacific is expected to gainsignificant traction in the global hepatocellular carcinoma drugs market owingto rising number of research and development activities undertaken by themanufacturers in the region to develop effective therapies. For instance, inFebruary 2017, Daiichi Sankyo, a pharmaceutical company in Japan completed thePhase-3 study of tivantinib indicated for patients with hepatocellularcarcinoma treated with other therapies.
Hepatocellular carcinoma (HCC) isa major type of primary liver cancer that arises from the liver cells orhepatocytes. The disease is found to occur mainly in patients with hepatitis B,hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellularcarcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, andliver biopsy. Treatment for hepatocellular carcinoma mainly includes radiationtherapy, ablation therapy in addition to chemotherapy and targeted drugtherapy. A majority of the HCC patients are diagnosed at the end-stage of liverdysfunction. Due to poor prognosis of the condition, mortality rate isapproximately the same as the incidence rate. Therefore, early detection of thecancer is an important parameter to improve the survival of affected patients,thus aiding in growth of the global hepatocellular carcinoma drugs market.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1596
Market Dynamics
Increasing incidence of globalhepatocellular carcinoma cases is a major factor augmenting market growth.According to the research by International Journal of Cancer Research andTreatment, 2014, HCC is the sixth most common type of cancer worldwide andthird most common cause of death worldwide, fifth for men and eighth for women.The disease accounts for more than 5% of all cancers and for 80-90% of primaryliver cancers. Also, according to the Addis Ababa University, 2017,hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancerand 810,000 related deaths in 2015. Furthermore, increasing incidence andmortality of hepatocellular carcinoma is attributed to the emergence of newrisk factors such as hepatitis B and C viral infections, metabolic disorderssuch as diabetes and non-alcoholic fatty liver disease, and exposure to toxinssuch as alcohol and aflatoxin.
Moreover, clinical advancementsintegrated with the approval of novel drugs by the regulatory agencies fortreating hepatocellular carcinoma is augmenting growth of the market. Forinstance, in April 2017, the U.S. Food & Drug Administration expanded theindications of regorafenib (Stivarga) manufactured by Bayer HealthCarePharmaceuticals Inc., for treatment of patients with hepatocellular carcinoma.The therapy showed significant improvement in survival for patients after thefailure of standard treatments. Also, in 2017, the U.S. FDA granted acceleratedapproval for nivolumab (Opdivo) drug developed by Bristol-Myers Squibb for thetreatment of hepatocellular carcinoma.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/hepatocellular-carcinoma-drugs-market-1596
However, the side effectsassociated with the drugs such as anemia, constipation, low white blood cellcount, pneumonia are the factors restraining growth of the market.
Competitive Analysis
The manufactures are focused onstrategic collaborations to jointly develop and commercialize immunotherapies indicatedto treat broad range of tumors. For instance, in 2014, Bristol-Myers SquibbCompany and Ono Pharmaceutical Co., Ltd. signed a strategic collaborationagreement to jointly develop and commercialize multiple immunotherapies assingle agents and combination therapies with Opdivo, to help address the unmetmedical needs of patients with cancer in Japan, South Korea and Taiwan. Also,in 2015, Novartis Pharmaceuticals initiated the Phase 2 trials to compare thesafety and efficacy for dovitinib and sorafenib in adult patients with advancedhepatocellular carcinoma.
Key players operating in theglobal hepatocellular carcinoma drugs market include Novartis Pharmaceuticals,Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc.,Johnson & Johnson, Celgen Corporation, Amgen Inc., Teva PharmaceuticalIndustries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1596
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
